GREGOR, Jakub, Yochai ADIR, Martina STERCLOVA, Nesrin MOGULKOC, Mordechai R KRAMER, Martina DOUBKOVÁ, Martina PLACKOVA, Veronika MULLER, Michael STUDNICKA, Monika ZURKOVA, Ladislav LACINA, Katarzyna LEWANDOWSKA, Vladimir BARTOS, Petra OVESNÁ, Ondřej MÁJEK and Martina KOZIAR VASAKOVA. The Impact of Switching to a Second Antifibrotic in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective Multicentre Study From the EMPIRE Registry. ARCHIVOS DE BRONCONEUMOLOGIA. BARCELONA: ELSEVIER ESPANA SLU, 2024, vol. 60, No 2, p. 80-87. ISSN 0300-2896. Available from: https://dx.doi.org/10.1016/j.arbres.2023.12.002.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The Impact of Switching to a Second Antifibrotic in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective Multicentre Study From the EMPIRE Registry
Authors GREGOR, Jakub (203 Czech Republic, belonging to the institution), Yochai ADIR, Martina STERCLOVA (203 Czech Republic), Nesrin MOGULKOC, Mordechai R KRAMER, Martina DOUBKOVÁ (203 Czech Republic, belonging to the institution), Martina PLACKOVA (203 Czech Republic), Veronika MULLER, Michael STUDNICKA (203 Czech Republic), Monika ZURKOVA (203 Czech Republic), Ladislav LACINA (203 Czech Republic), Katarzyna LEWANDOWSKA, Vladimir BARTOS (203 Czech Republic), Petra OVESNÁ (203 Czech Republic, belonging to the institution), Ondřej MÁJEK (203 Czech Republic, belonging to the institution) and Martina KOZIAR VASAKOVA (203 Czech Republic).
Edition ARCHIVOS DE BRONCONEUMOLOGIA, BARCELONA, ELSEVIER ESPANA SLU, 2024, 0300-2896.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30203 Respiratory systems
Country of publisher Spain
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 8.000 in 2022
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.arbres.2023.12.002
UT WoS 001170483700001
Keywords in English Registries; Antifibrotic agents; Survival; Treatment switch
Tags 14110215, 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 3/5/2024 13:39.
Abstract
Introduction: Most patients with idiopathic pulmonary fibrosis (IPF) treated with antifibrotics (AF) have progressive disease despite treatment. A switch of AF may improve survival, but evidence from randomised controlled trials is missing. We aimed to evaluate the efficacy of an AF switch on survival and FVC decline in patients from the European MultiPartner IPF registry (EMPIRE). Methods: The study included 612 patients who discontinued the first antifibrotic therapy. Patients were grouped and analysed from two perspectives: (1) whether they had received a second antifibrotic treatment after the discontinuation of the first therapy, and (2) a reason for discontinuation of the first AF - "lack of efficacy" (LE) and "intolerance" (INT). Results: While 263 (43%) of 612 patients received no second AF ("non-switched"), 349 (57%) patients switched. Overall survival was higher in patients who received a second AF (median 50 vs. 29 months; adjusted HR 0.64, P=0.023). Similarly, the annual FVC decline was significantly reduced in switched patients: -98ml/y in switched and -172ml/y in non-switched patients (P=0.023), respectively. The switched patients had similar risk for mortality in both LE and INT groups (adjusted HR 0.95, P=0.85). The high impact of switching on survival was demonstrated in LE patients (adjusted HR 0.27, P<0.001). Conclusion: The patients without a second AF had significantly shorter overall survival. Our analysis suggests the importance of switching patients with an ineffective first AF therapy to a second AF therapy.
PrintDisplayed: 29/6/2024 10:58